NCT06573723 Institutional Registry of Rare Diseases
| NCT ID | NCT06573723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Italiano de Buenos Aires |
| Condition | Rare Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 380 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2034-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 380 participants in total. It began in 2024-07-01 with a primary completion date of 2034-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.
Eligibility Criteria
Inclusion Criteria: * Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome. * Must be followed at Hospital Italiano de Buenos Aires. Exclusion Criteria: \- Refusal to participate in the study or in the informed consent process.
Contact & Investigator
Marcelo Serra, PhD
PRINCIPAL INVESTIGATOR
HIBA
Frequently Asked Questions
Who can join the NCT06573723 clinical trial?
This trial is open to participants of all sexes, studying Rare Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06573723 currently recruiting?
Yes, NCT06573723 is actively recruiting participants. Contact the research team at maria.posadas@hospitalitaliano.org.ar for enrollment information.
Where is the NCT06573723 trial being conducted?
This trial is being conducted at Buenos Aires, Argentina.
Who is sponsoring the NCT06573723 clinical trial?
NCT06573723 is sponsored by Hospital Italiano de Buenos Aires. The principal investigator is Marcelo Serra, PhD at HIBA. The trial plans to enroll 380 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.